B. Riley Comments on MediciNova's Q2 Earnings (NASDAQ:MNOV)

MediciNova, Inc. (NASDAQ:MNOV - Free Report) - Equities researchers at B. Riley issued their Q2 2025 earnings estimates for MediciNova in a research note issued on Monday, June 16th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings per share of ($0.07) for the quarter. B. Riley currently has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for MediciNova's current full-year earnings is ($0.24) per share. B. Riley also issued estimates for MediciNova's Q3 2025 earnings at ($0.08) EPS and Q4 2025 earnings at ($0.10) EPS.

A number of other equities analysts have also recently commented on MNOV. Wall Street Zen began coverage on MediciNova in a report on Sunday, May 18th. They set a "hold" rating for the company. D. Boral Capital restated a "buy" rating and set a $9.00 price objective on shares of MediciNova in a research report on Wednesday, April 9th.

MediciNova Stock Performance

Shares of MNOV stock opened at $1.33 on Tuesday. MediciNova has a 52 week low of $1.12 and a 52 week high of $2.55. The company has a 50-day simple moving average of $1.43 and a 200 day simple moving average of $1.70. The company has a market capitalization of $65.23 million, a price-to-earnings ratio of -5.78 and a beta of 0.42.

MediciNova (NASDAQ:MNOV - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.08.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MNOV. Y Intercept Hong Kong Ltd purchased a new position in shares of MediciNova during the 4th quarter valued at $78,000. SBI Securities Co. Ltd. purchased a new position in MediciNova in the 4th quarter worth approximately $113,000. Geode Capital Management LLC increased its stake in shares of MediciNova by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 514,914 shares of the biopharmaceutical company's stock valued at $1,082,000 after buying an additional 8,948 shares during the period. Barclays PLC grew its stake in MediciNova by 15.5% in the fourth quarter. Barclays PLC now owns 95,600 shares of the biopharmaceutical company's stock worth $201,000 after purchasing an additional 12,800 shares during the period. Finally, Jane Street Group LLC grew its stake in shares of MediciNova by 64.5% in the fourth quarter. Jane Street Group LLC now owns 23,259 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 9,121 shares during the last quarter. Hedge funds and other institutional investors own 9.90% of the company's stock.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.